ProCE Banner Activity

Don’t Delay With Delta: Best Practices and Calls to Action in HDV

Slideset Download
Comprehensive slideset updated regularly to include the latest data and guideline updates for hepatitis delta virus (HDV).

Released: July 25, 2022

Expiration: July 24, 2023

Share

Faculty

Joseph (Patient)

Joseph (Patient)

Maria Buti

Maria Buti, MD

Professor of Medicine
Senior Consultant
Hospital Universitario Valle Hebron
Barcelona, Spain

Richard H. Davis

Richard H. Davis, PA-C

Senior PA
Gastroenterology
University of Florida
UF Health
Gainesville, Florida

Robert G. Gish

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Nancy Reau

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Stefan Zeuzem

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Maria Buti, MD

Professor of Medicine
Senior Consultant
Hospital Universitario Valle Hebron
Barcelona, Spain

Maria Buti, MD, has disclosed that she has received consulting fees and funds for research support from Gilead Sciences and Janssen.

Richard H. Davis, PA-C

Senior PA
Gastroenterology
University of Florida
UF Health
Gainesville, Florida

Richard H. Davis, PA-C, has no relevant conflicts of interest to report.

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, and Viking Therapeutics; has served on advisory boards for Abbott, AbbVie, Antios, Arrowhead, Bayer, Biocollections, Dova, Eiger, Enyo, Fibronostics, Fujifilm/Wako, Gilead Sciences, HepQuant, Intercept, Janssen, Merck, Prodigy, and Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, and CymaBay Therapeutics.

Joseph (Patient),

Joseph has disclosed that he has received fees for non-CME/CE services from Gilead Pharmaceuticals, Janssen Pharmaceuticals, and Vir Biotechnology.

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received funds for research support paid to her institution from AbbVie and Gilead Sciences and consulting fees from AbbVie, Arbutus, Gilead Sciences, Intercept, and Salix.

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has received consulting fees from AbbVie, BioMarin, Gilead Sciences, Janssen, Intercept, and Sobi and fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen, and Merck/MSD.